LifeCycle Pharma, Major Shareholder Announcements


Company Announcement no. 1/2009
To: NASDAQ OMX Copenhagen A/S	Hørsholm,  Denmark, January 27, 2009
Major Shareholder Announcements

Hørsholm, Denmark, 27 January 2009; In accordance with Section 29 of the
Securities Trading Act LifeCycle Pharma A/S (OMX: LCP) today announced that LCP
has received a notification from H. Lundbeck A/S that it has decreased its
shareholdings in LCP from 15,313,816 shares, corresponding to 27.21%, to 0
shares. 

At the same time, LCP has received a notification that LFI A/S, 100 % owned by
the Lundbeck Foundation, now owns 15,878,066 shares, corresponding to 28.21%. 

For more information, please contact:
LifeCycle Pharma A/S				

Dr. Jim New
President & Chief Executive Officer		
Phone: +45 7033 3300				
Email: JSN@lcpharma.com

Or 

Peter Schøtt Knudsen
Head of Investor Relations
Phone: + 45 20553817
Email: PSK@lcpharma.com

About LifeCycle Pharma A/S (LCP)
Based in Hørsholm, Denmark, with an office in New York, LCP is an emerging
specialty pharmaceutical company. Clinical development is the core of LCP's
effort to develop a product portfolio which includes products for
immunosuppression, specifically organ transplantation, and products to combat
certain cardiovascular diseases. As a fully integrated company, LCP adapts new
technologies on a fast commercial timetable. LCP's unique, patented delivery
technology, MeltDose®, can improve absorption and bioavailability - at
low-scale up costs - not only for a broad spectrum of drugs already on the
market but also for new chemical entities. LCP has a cholesterol-lowering
product, Fenoglide™, currently on the U.S. market and a diversified near- and
medium-term pipeline with five product candidates in clinical trials and one in
preclinical development. LCP is listed on the OMX Nordic Exchange Copenhagen
under the trading symbol (OMX: LCP). For further information, please visit
www.lcpharma.com. 

Attachments

270109_lifecycle pharma major sharholder information.pdf